Medtronic Reports Strong FY25 Results and Dividend Increase

Medtronic ( (MDT) ) has released its Q4 earnings. Here is a breakdown of the information Medtronic presented to its investors.

Medtronic plc, headquartered in Galway, Ireland, is a leading global healthcare technology company that develops and manufactures medical devices and therapies to address a wide range of health conditions, including cardiac devices, surgical tools, and insulin pumps.

Medtronic has reported a strong finish to its fiscal year 2025, with a notable increase in revenue and earnings per share. The company also announced a dividend increase, marking the 48th consecutive year of such an increase, and revealed plans to separate its Diabetes business into a standalone public company.

Key financial highlights from the fourth quarter include a 3.9% increase in revenue to $8.9 billion, a 67% rise in GAAP diluted EPS to $0.82, and an 11% increase in non-GAAP diluted EPS to $1.62. The company’s operating margin also improved significantly, with a 380 basis point increase in GAAP terms. Medtronic’s FY25 revenue reached $33.5 billion, with a 3.6% increase as reported and a 4.9% organic growth. The company returned $6.3 billion to shareholders and achieved a free cash flow of $5.2 billion.

Medtronic’s strategic initiatives include the submission of the Hugo™ RAS system to the FDA and the launch of BrainSense™ Adaptive Deep Brain Stimulation. The company also announced a leadership transition in its Cardiovascular Portfolio and highlighted the strong performance of its Cardiac Ablation Solutions and Diabetes divisions.

Looking ahead, Medtronic’s management is optimistic about continued growth, with guidance for FY26 organic revenue growth of approximately 5% and non-GAAP EPS growth of about 4%. The company remains focused on leveraging its key growth drivers and mitigating potential impacts from tariffs.